Abstracts

675 – Outcomes on Cabotegravir + Rilpivirine in Suppressed People With HIV (PWH) in TRIO Health US Cohort

Background Cabotegravir+Rilpirivine (CAB+RPV) is the first complete long-acting injectable antiretroviral therapy (ART) for the treatment of HIV for ART-experienced PWH with undetectable viral load (VL <50 copies/mL [cpm]). This study examined the utilization and effectiveness of CAB+RPV in real-world settings in the US. Methods ART-experienced adults with undetectable VL at initiation who received ≥1 CAB+RPV injection…

776 – Performance Evaluation of the Xpert Hepatitis B Molecular Test Among Pregnant Women in Uganda

Background To prevent child-mother-to-child transmission of hepatitis B (HBV PMTCT), the World Health Organization recommends HBV screening among pregnant women, testing for HBV DNA, prophylactic antivirals, and hepatitis B birth dose vaccination to newborns. Uganda is utilizing its existing HIV platforms to integrate Hepatitis B services as part of the triple-elimination strategy. While HBV screening has improved,…

782 – Simulation Modeling of Hepatitis B Virus Disease Progression, Hepatitis Flares, and Functional Cure

Background Nearly 300 million people have chronic hepatitis B infection (HBV), which can result in hepatic complications (e.g., cirrhosis and hepatocellular carcinoma [HCC]) and mortality. Our objective was to develop and validate an HBV simulation model to examine disease progression, treatment, and cure.  Methods We developed an HBV simulation model with nine health states: HBV-uninfected;…

726 – HIV-1 Env Exhibits Distinct Conformations and Neutralization Profiles in CSF and Blood

Background HIV-1 replicates in different body compartments and sub-compartments characterized by distinct compositions of small solutes and proteins. It is often assumed that virus proteins maintain the same conformation, function and sensitivity to inhibitors in different molecular environments, in vivo and in vitro. The protein albumin shows remarkable variability in concentration between the blood and…

689 – Long-Term Virologic Suppression Rates in the Ward 86 HIV Clinic’s Long-Acting ART Program (SPLASH)

Background The Ward 86 HIV Clinic in San Francisco serves publicly-insured people with HIV (PWH) living with multiple concomitant challenges. With the approval of long-acting (LA) cabotegravir/rilpivirine in 2021, Ward 86 started using LA antiretroviral therapy (ART) for those with adherence challenges to oral ART.  More than 3.5 years into the program, we now report…

641 – Fixed Dosing Versus Body-Weight-Based Dosing of HIV-1 Prophylactic Monoclonal Antibodies in Adults

Background Body-weight-based dosing has been typically used in phase 1 trials of therapeutic and prophylactic monoclonal antibodies (mAbs). In recent years, pharmacokinetics (PK) modeling and simulations aided label changes of multiple marketed mAbs for alternative fixed dosing regimens that reduce inter-individual PK variability while maintaining the same average mAb concentrations. We aimed to evaluate fixed…

686 – Implementation of LA-CAB/RPV in US Clinic Settings: A Survey of Front-Line Clinicians

Background Long-acting Cabotegravir and Rilpivirine (LA-CAB/RPV), approved in January 2021, is the first complete injectable regimen for virologically suppressed patients with HIV-1 without a history of resistance. The availability of LA-CAB/RPV offers a significant opportunity to expand the landscape of care for people with HIV. However, data on its implementation outside of early phase clinical…

761 – Incidence and Impact of Hepatic Steatosis in People With HIV: Insights From the NA-ACCORD Cohort

Background Hepatic steatosis is an increasingly important comorbidity in aging people with HIV (PWH). Population-representative estimates of incidence, risk factors and association with liver-related events are not well understood. We evaluated the incidence of hepatic steatosis and its association with liver-related events and overall mortality within the NA-ACCORD. Methods Hepatic steatosis was defined using the…